致：浙江我武生物科技股份有限公司 上海礼丰律师事务所(以下简称"本所")接受浙江我武生物科技股份有限公司 (以下简称"公司")的委托，指派本所律师(以下简称"本所律师")根据《中华人民共 和国证券法》《中华人民共和国公司法》《上市公司股东会规则》等法律、法规、 规范性文件(以下统称"法律法规")及《浙江我武生物科技股份有限公司章程》(以 下简称"公司章程")的规定就公司 2025 年第一次临时股东会(以下简称"本次股东 会")相关事宜出具法律意见。 关于浙江我武生物科技股份有限公司 2025 年第一次临时股东会的法律意见书 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定及法律意 见书出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽 责和诚实信用原则，进行了充分的核查验证，保证法律意见所认定的事实真实、 准确、完整、及时，所发表的结论性意见合法、准确，不存在虚假记载、误导性 陈述或者重大遗漏，并承担相应法律责任。 本所律师已经按照有关法律法规的要求和律师行业公认的道德标准以及勤 勉尽责的精神对公司本次股东会相 ...

证券代码：300357 证券简称：我武生物 公告编号：2025-035 号 浙江我武生物科技股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东会没有出现否决议案的情况； 2. 本次股东会不涉及变更以往股东会已通过决议的情况。 一、会议召开和出席情况 1. 会议召集人：浙江我武生物科技股份有限公司（以下简称"公司"）董事会 其中，通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 9 月 12 日 9:15-9:25、9:30-11:30 和 13:00-15:00；通过深圳证券交易所互联网投票系统进行网络投 票的具体时间为 2025 年 9 月 12 日 9:15-15:00。 3. 会议召开方式：采用现场表决与网络投票相结合的方式召开 4. 现场会议地点：上海市徐汇区钦江路 333 号 40 号楼 6 楼会议室 5. 会议主持人：董事长胡赓熙先生 6. 本次会议的召集、召开、表决程序符合有关法律法规和《公司章程》的规定。 7. 会议出席情况 股东出席的总体情况： 2. 会议 ...

Core Viewpoint - The report emphasizes the sustained high growth in the innovative pharmaceutical and medical device sectors, recommending continued investment in these areas [1]. Investment Highlights - The report maintains a recommendation for innovative pharmaceuticals and medical devices, highlighting the potential for value re-evaluation in the Pharma sector, with specific buy ratings for companies such as 恒瑞医药, 翰森制药, 三生制药, and 华东医药 [2]. - It continues to recommend Biopharma/Biotech companies that are gradually realizing their innovative pipelines and entering a performance growth phase, with buy ratings for 科伦博泰生物, 信达生物, 康方生物, 新诺威, 映恩生物, 京新药业, 微芯生物, 特宝生物, 我武生物, and 来凯医药 [2]. - The report also suggests investment in CXO and upstream pharmaceutical companies benefiting from innovation and recovery, maintaining buy ratings for 百普赛斯, 药明康德, 药明合联, 泰格医药, and 美诺华 [2]. - It recommends leading medical device companies expected to recover, with buy ratings for 微创医疗, 联影医疗, and 惠泰医疗 [2]. Market Performance - In the first week of September 2025, the A-share pharmaceutical sector outperformed the broader market, with the SW pharmaceutical and biotech index rising by 1.4% while the Shanghai Composite Index fell by 1.2% [3]. - Within the biopharmaceutical sector, the chemical preparations segment saw a notable increase of 4.5%, while biological products and medical services rose by 1.9% and 1.7%, respectively [3]. - The top-performing stocks included 海辰药业 (+28.7%), 长春高新 (+24.2%), and 百花医药 (+21.3%), while the worst performers were 舒泰神 (-24.0%), 广生堂 (-15.8%), and 塞力医疗 (-15.6%) [3]. - In the Hong Kong market, the healthcare sector also outperformed, with the Hang Seng Healthcare index rising by 7.0% and the biotech index by 7.3%, compared to a 1.4% increase in the Hang Seng Index [3]. - The top gainers in the Hong Kong market were 三叶草生物-B (+99%), 圣诺医药-B (+62%), and 加科思-B (+41%), while the biggest losers included 美中嘉和 (-11%), 科笛-B (-9%), and 思路迪医药股份 (-6%) [3]. - In the US market, the healthcare sector performed in line with the broader market, with the S&P Healthcare Select Sector Index increasing by 0.3%, matching the S&P 500's performance [4]. - The top gainers in the US healthcare sector included 德康医疗 (+7%), 生物基因 (+6%), and 环球健康服务 (+5%), while the largest declines were seen in KENVUE (-10%), REVVITY (-4%), and MOLINA HEALTHCARE (-3%) [4].

昨日基金共对26家公司进行调研，扎堆调研恺英网络、兴齐眼药、我武生物等。 证券时报·数据宝统计，9月1日共43家公司被机构调研，按调研机构类型看，基金参与26家公司的调研 活动，其中，5家以上基金扎堆调研公司共12家。恺英网络最受关注，参与调研的基金达34家；兴齐眼 药、博思软件等分别获24家、9家基金集体调研。 基金参与调研的公司中，按所属板块统计，深市主板公司有11家，创业板公司有10家，沪市主板公司有 2家，科创板公司有2家，北交所公司有1家。所属行业来看，基金调研的公司共涉及17个行业，所属电 力设备、电子、医药生物等行业个股最多，均有3只个股上榜。 市场表现上，基金调研股中，近5日上涨的有10只，涨幅居前的有坤恒顺维、兴齐眼药、华力创通等， 涨幅为15.13%、14.77%、14.39%；下跌的有16只，跌幅居前的有广信科技、祥生医疗、珠城科技等， 跌幅为8.37%、7.83%、7.57%。 数据宝统计，基金参与调研股中，近5日资金净流入的有7只，博杰股份近5日净流入资金1.12亿元，主 力资金净流入最多；净流入资金较多的还有三晖电气、蒙娜丽莎等，净流入资金分别为8267.21万元、 5085.94 ...

Group 1: Company Analysis - Weichai Power - Weichai Power's 2025 interim report shows significant growth in data center large-capacity engines, with nearly 600 units sold, representing a 491% year-on-year increase [4] - The company's AIDC business is rapidly developing, and the KION logistics equipment business is expected to improve profitability after management optimization [2][4] - Weichai Power's revenue for the first half of 2025 was CNY 1131.5 billion, a slight increase of 0.6% year-on-year, while net profit attributable to shareholders was CNY 56.4 billion, down 4.4% year-on-year [3][4] Group 2: Company Analysis - Tuojing Technology - Tuojing Technology's advanced process verification equipment has successfully passed customer certification and is gradually entering the mass production phase, leading to a significant improvement in profitability [13][14] - The company's revenue for the first half of 2025 reached CNY 1.954 billion, a year-on-year increase of 54.25%, with a net profit of CNY 38.18 million, up 91.35% year-on-year [14] - The sales gross margin for Q2 2025 was 38.82%, indicating a clear upward trend in profitability [14] Group 3: Company Analysis - Iwu Biological - Iwu Biological's core product, dust mite drops, is steadily growing, while the new product, Artemisia annua drops, is rapidly gaining market share [17][18] - The company reported a revenue of CNY 484 million for the first half of 2025, a year-on-year increase of 12.81%, and a net profit of CNY 177 million, up 18.61% year-on-year [17][18] - The company is focusing on new research directions, including stem cells and natural medicines, which may enhance its growth potential [18] Group 4: Industry Analysis - Textile and Apparel - The textile and apparel industry faces significant operational challenges, with A-share apparel revenue declining in Q2, although some companies are showing strong performance [7][10] - The retail sales of clothing and accessories in China showed a year-on-year increase of 1.8% in July, indicating a slight recovery in consumer demand [9] - The export of textiles and garments from China saw a year-on-year decline of 0.3% in July, with garment exports weakening [9][11]

证券代码：300357 证券简称：我武生物 公告编号：2025-034 号 浙江我武生物科技股份有限公司 关于控股股东与实际控制人之间通过大宗交易方式转让公 司股份计划期限届满的公告 股东浙江我武管理咨询有限公司保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 截至本公告披露日，本次股份减持计划期限已届满，我武咨询未减持公司股 份。公司控股股东浙江我武管理咨询有限公司与实际控制人之一的胡赓熙先生所 持公司股份未发生变化，具体情况如下： 1 | 股东名称 | 股份性质 | 股数(股) | 占总股本比例(%) | | --- | --- | --- | --- | | 浙江我武管理 咨询有限公司 | 合计持有股份 | 203,454,131 | 38.86% | | | 其中：无限售条件股份 | 203,454,131 | 38.86% | | | 有限售条件股份 | - | - | | 胡赓熙 | 合计持有股份 | 43,698,370 | 8.35% | | | 其中：无限售条件股份 | 10, ...

Group 1: Company Performance and Sales Strategy - The company experienced a recovery in performance starting from the second half of last year, attributed to the appointment of young sales managers who are taking on more responsibilities in various regions [2] - Adjustments to the sales management structure have led to improved efficiency and a more refined management model [2] - Future sales performance will be disclosed in the company's regular reports [2] Group 2: Research and Development Progress - The subsidiary is currently developing allogeneic mesenchymal stem cell therapies, which are in the preclinical research stage [3] - The main challenge in stem cell drug development is ensuring consistent production quality due to variability in the source, culture medium, and methods used [3] - The company has several products in the clinical trial phase, including "Dust Mite Membrane Agent" and diagnostic patches for dermatitis, with the latter entering Phase I clinical trials in August 2025 [3] Group 3: Product Promotion and Market Strategy - The company has launched eight skin prick test products, shifting their positioning from auxiliary desensitization treatments to allergen screening tools [4] - The National Healthcare Security Administration has issued guidelines that allow for the aggregation of charges for different allergen skin tests, which may affect pricing strategies [4] Group 4: Investment in Research and Development - In the first half of 2025, the company invested approximately 61,682,073.51 yuan in R&D, accounting for 12.74% of its revenue [4] - As of June 2025, the company and its subsidiaries employed over 260 R&D personnel, primarily trained in-house [5]

Group 1 - The company's revenue from dust mite drops is gradually recovering, with a revenue of 484 million yuan in the first half of 2025, representing a year-on-year increase of 12.81%, and a net profit of 177 million yuan, up 18.61% year-on-year [1] - The sales revenue of dust mite drops reached 455 million yuan, showing a year-on-year growth of 10.51%, while the sales revenue of Artemisia pollen sublingual drops increased significantly by 71.37% to 21 million yuan [1] - The company has effectively controlled expenses, with a net profit margin of 38.66% in Q2 2025, an increase of 6.4 percentage points year-on-year [1] Group 2 - The company is optimistic about the growth potential of Artemisia pollen drops and allergen prick test products, which are expected to contribute to a second growth curve [2] - The approval of Artemisia pollen drops in January 2021 and the addition of pediatric indications in May 2023 are expected to drive sales growth [2] - The company has launched eight allergen prick test products, which will enhance diagnostic business and increase the penetration rate of allergen testing, supporting the growth of therapeutic desensitization drugs [2] Group 3 - Revenue forecasts for 2025-2027 are projected at 1.054 billion, 1.213 billion, and 1.475 billion yuan, with net profits of 382 million, 454 million, and 581 million yuan respectively, corresponding to PE ratios of 43, 36, and 28 times [3] - The high incidence of allergic rhinitis and asthma, along with increasing recognition of desensitization treatment guidelines, supports the long-term penetration of desensitization therapies [3] - The company initiates coverage with a "buy" rating based on these growth prospects [3]

Core Viewpoint - Iwubio has demonstrated strong growth in revenue and profit in the first half of 2025, driven by its leading position in the allergen desensitization treatment market and the introduction of new products [1][2][3]. Financial Performance - In the first half of 2025, Iwubio achieved revenue of 484 million yuan, a year-on-year increase of 12.81% [1] - The company's net profit attributable to shareholders was 177 million yuan, up 18.61% year-on-year [1] - The revenue from dust mite drops was 455 million yuan, growing by 10.51% [1] - The revenue from the mugwort pollen sublingual drops reached 21.02 million yuan, with a significant increase of 71.37% [1] - The skin prick solution generated revenue of 6.33 million yuan, marking a growth of 104.38% [1] Market Position and Product Development - Iwubio is a core supplier in China's desensitization treatment market, with only its products approved for sublingual allergen desensitization therapy [1][3] - The company has a unique advantage in the allergen product field, which supports its continuous growth [3] - Iwubio has expanded its product matrix with the approval of new skin prick solutions for various allergens [3] Industry Growth Potential - The Chinese allergy drug market is expected to reach 21.6 billion USD by 2030, with a CAGR of 17.1% from 2022 to 2030 [2] - The increasing awareness of allergic diseases among the population and their rising incidence rates are driving market growth [2] Research and Development - Iwubio invested 61.68 million yuan in R&D in the first half of 2025, accounting for 12.74% of its revenue [4] - The company holds 13 valid Chinese invention patents and 7 foreign invention patents, establishing a solid technological barrier [4] - Iwubio is actively involved in clinical research, with numerous studies published in international journals supporting the clinical value of its products [5][6] Future Expansion - Iwubio is exploring new markets, including stem cell therapy and antibiotic resistance, which are projected to have significant growth potential [7][8] - The company aims to enhance its product offerings in the allergy treatment sector while also venturing into emerging medical fields [8]

Core Insights - The social security fund has invested in 396 stocks by the end of Q2, with 37 stocks held for over 20 consecutive quarters, indicating a focus on long-term investments [1][2] Group 1: Investment Trends - The social security fund has consistently held shares in 204 stocks for over four quarters, with 132 stocks held for more than two years [1] - The longest-held stock is Hualu Hengsheng (华鲁恒升), held for 51 quarters since Q4 2012, with a total holding of 133 million shares, accounting for 6.26% of the circulating shares [1][4] - Other long-term holdings include Zhongyuan Media (中原传媒) and WoW Bio (我武生物), held for 44 and 43 quarters respectively [1] Group 2: Stock Performance - Among the 37 stocks held for over five years, the top holdings by quantity are Changshu Bank (常熟银行) with 206 million shares, Sun Paper (太阳纸业) with 151 million shares, and Hualu Hengsheng with 133 million shares [2] - The stocks with the highest holding ratios include Keri International (科锐国际) at 6.30%, Hualu Hengsheng at 6.26%, and Changshu Bank at 6.23% [2] - In terms of changes in holdings, 12 stocks saw an increase in holdings, with significant increases for Three Squirrels (三只松鼠) at 283.29%, Hongfa Co. (宏发股份) at 76.77%, and Hangyang Co. (杭氧股份) at 42.03% [2] Group 3: Industry Distribution - The 37 stocks are concentrated in the basic chemical, electronics, and automotive industries, with 7, 3, and 3 stocks respectively [3] - The basic chemical sector includes Hualu Hengsheng, Yangnong Chemical (扬农化工), and Blue Sky Technology (蓝晓科技) [3] - The electronics sector includes Transsion Holdings (传音控股), Pengding Holdings (鹏鼎控股), and XW Communication (信维通信) [3] Group 4: Financial Performance - Among the 37 stocks, 24 reported year-on-year profit growth, with notable increases from China Jushi (中国巨石) at 75.51%, Jieput (杰普特) at 73.84%, and New Hecheng (新和成) at 63.46% [3] - Conversely, 12 stocks experienced a decline in net profit, with the largest decreases from Zhongqi Co. (中旗股份) at 240.99%, Sanyou Chemical (三友化工) at 77.64%, and Three Squirrels at 52.22% [3]